These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15760401)

  • 1. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience.
    Trofe J; Buell JF; Beebe TM; Hanaway MJ; First MR; Alloway RR; Gross TG; Succop P; Woodle ES
    Am J Transplant; 2005 Apr; 5(4 Pt 1):775-80. PubMed ID: 15760401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry.
    Aull MJ; Buell JF; Trofe J; First MR; Alloway RR; Hanaway MJ; Wagoner L; Gross TG; Beebe T; Woodle ES
    Transplantation; 2004 Dec; 78(11):1676-82. PubMed ID: 15591959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
    Rouphael B; Lankireddy S; Lazaryan A; Kukla A; Ibrahim HN; Matas AJ; Issa N
    Clin Transplant; 2016 Jan; 30(1):60-5. PubMed ID: 26497471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
    Zierhut H; Kanzelmeyer N; Buescher A; Höcker B; Mauz-Körholz C; Tönshoff B; Metzler M; Pohl M; Pape L; Maecker-Kolhoff B
    Pediatr Transplant; 2021 Sep; 25(6):e14042. PubMed ID: 34021949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - a national study.
    Cleper R; Ben Shalom E; Landau D; Weissman I; Krause I; Konen O; Rahamimov R; Mor E; Bar-Nathan N; Frishberg Y; Davidovits M
    Pediatr Transplant; 2012 Sep; 16(6):619-26. PubMed ID: 22708682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients.
    Francis A; Johnson DW; Craig J; Teixeira-Pinto A; Wong G
    Kidney Int; 2018 Oct; 94(4):809-817. PubMed ID: 30173897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small intestinal involvement by lymphoproliferative disorders post-renal transplantation: a report from the post-transplant lymphoproliferative disorder international survey.
    Khedmat H; Taheri S
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):487-94. PubMed ID: 23640619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes.
    Pan K; Franke AJ; Skelton WP; Bishnoi R; Shah C; Dang NH; Alquadan K
    Leuk Lymphoma; 2021 May; 62(5):1123-1128. PubMed ID: 33327817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
    Cockfield SM; Preiksaitis JK; Jewell LD; Parfrey NA
    Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
    Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
    Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
    OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
    Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
    Kumarasinghe G; Lavee O; Parker A; Nivison-Smith I; Milliken S; Dodds A; Joseph J; Fay K; Ma DD; Malouf M; Plit M; Havryk A; Keogh AM; Hayward CS; Kotlyar E; Jabbour A; Glanville AR; Macdonald PS; Moore JJ
    J Heart Lung Transplant; 2015 Nov; 34(11):1406-14. PubMed ID: 26279197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience.
    Buell JF; Gross TG; Hanaway MJ; Trofe J; Muthiak C; First MR; Alloway RR; Woodle ES
    Transplant Proc; 2005 Mar; 37(2):956-7. PubMed ID: 15848588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry.
    Caillard S; Lelong C; Pessione F; Moulin B;
    Am J Transplant; 2006 Nov; 6(11):2735-42. PubMed ID: 17049061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and prognosis of post-transplant lymphoproliferative disorders within renal allograft: Report from the PTLD.Int. Survey.
    Khedmat H; Taheri S
    Ann Transplant; 2010; 15(3):80-6. PubMed ID: 20877272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.
    Rosenberg AS; Klein AK; Ruthazer R; Evens AM
    Am J Hematol; 2016 Jun; 91(6):560-5. PubMed ID: 26928381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival.
    Serre JE; Michonneau D; Bachy E; Noël LH; Dubois V; Suberbielle C; Kreis H; Legendre C; Mamzer-Bruneel MF; Morelon E; Thaunat O
    Kidney Int; 2014 Jan; 85(1):182-90. PubMed ID: 23802193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.